Aims: To compare the quality of platelet concentrates obtained from buffy-coat stored in pooled plasma during days 1–5, those stored in additive solution during days 1–5 and 7 processed in UMAE HE Puebla Blood Bank, to evaluate the efficacy of platelet additive solutions. Methods: Leukoreduced platelet concentrates (LDPCs) were prepared from pools of four buffy-coats (BCs) suspended in pooled plasma (PP) (March–June 2018); and platelet additive solution (SSP+, Macopharma) (August–October 2019) as a validation process in UMAE HE Blood Bank, Puebla, Mexico. On days 1, 5 (PP), and the 7th day of storage (SSP+), samples were tested for CD45, CD42b, CD62P, and Annexin V (CyAn ADP-Beckman Coulter); pCO2, pO2, and pH (OPTI CCA-TS2); glucose, lactic dehydrogenase (LDH), and Total Proteins (Unicel DXC800-Beckman Coulter); and platelet count and media platelet volume (MPV) (Swilab Alfa—Boule). Results: Platelet recoveries from BC pooling did not present significant differences between PP and SSP+ methods (p >0.05). pH, MPV, and pO2 results were not affected by the storage medium during the storage period. Leukocyte concentration (CD45) complied in both groups with European standards. Glucose consumption and apoptosis markers were of lower values with PP platelets, and activation markers (CD62P) were higher with LDPC in PP (p > 0.05). Conclusion: In vitro analysis of the seven-day storage of LDPC in SSP+ revealed stability in pH with a lower expression of CD62p, among other biochemical markers. Therefore, LDPC in SSP+ is a sustainable product for transfusion with the equivalent quality compared with five-day storage platelets in PP.

Aims: To explore the compliance with European standards for the quality control (QC) parameters of blood components production in Latin American blood banks, evaluating QC data results processed with red blood cell (RBC), and platelet concentrates (PL) produced. Methods: An observational retrospective cross-sectional study was conducted with data from one year’s production QC data of platelet concentrate (PL) from the buffy-coat (BC) removal method. Red blood cell was collected in three blood banks from Mexico, Colombia, and Chile. Analysis of the quality limits established in each country was made using Pearson’s Chi-square test. Dunnett’s T3 test evaluated the comparative analysis of the mean. All the tests were performed with bilateral contrast, achieving statistical significance when p ≤ 0.05. Results: The mean of the total results for the RBC evaluated was volume 277 mL ± 21; hematocrit (HCT) 58.7% ± 3.6; leukocytes (×109/mL) 0.47 ± 0.31. Results for PL were volume: 67 ± 10; platelet count (×109/mL): 76.8 ± 24; leukocytes (×109/mL) 0.02 ± 0.02. According to these total results, the compliance with respect to the control performed was for RBC: Volume 97.9%; hematocrit 98.8%; leukocytes 97%. For PL was 100% for volume; platelet count 82.3%; leukocytes 95.3%. Conclusion: The QC results conclude that the RBC with the BC removal process produces high-quality components, with a reduced concentration of leukocytes, complying with European Union (EU) guidelines and allow to obtain single platelet from BC with high quality.